Skip to search formSkip to main contentSkip to account menu

niraparib

Known as: 2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide 
An inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Niraparib inhibits PARP activity, enhancing the… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (3)

IndazolesPiperidinesPoly(ADP-ribose) Polymerase Inhibitors

Narrower (1)

MK 4827
NCIt Antineoplastic Agent TerminologyPARP1 protein, human

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
In the March 2019 issue of Pharmacoeconomics, Guy et al. evaluated the cost effectiveness of niraparib compared with routine… 
2018
2018
Human mass balance and metabolite profiling studies of the new anticancer agents plitidepsin, lurbinectedin and niraparib
There is a vast increase in the number of newly developed anticancer therapeutics, of which marine-derived anticancer drugs and… 
2017
2017
FDA approvals for the first 6 months of 2017
2016
2016
Niraparib Slows Ovarian Cancer Progression.
Results from a phase III trial indicate that maintenance therapy with the PARP inhibitor niraparib is more effective than placebo… 
2016
2016
Abstract 4353: Preclinical evaluation of the PARP inhibitor niraparib and cytotoxic chemotherapy alone or in combination in a panel of 25 triple-negative breast cancer PDX models: Relevance of BRCA…
Poly-ADP-ribose polymerase 1 (PARP) inhibitors are therapeutically effective in a subset of breast and high-grade ovarian cancers… 
2015
2015
Abstract P5-06-04: The PARP inhibitor niraparib demonstrated activity in patient-derived triple-negative breast cancer xenograft models with high homologous recombination deficiency (HRD) score
Triple negative breast cancer (TNBC), which comprises 15% of all breast cancers, has a poor prognosis and currently lacks… 
2015
2015
A phase 2, open-label study of niraparib in women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer after >=3 previous chemotherapy regimens.
TPS5609 Background: Niraparib is a potent, orally active PARP-1 and -2 inhibitor in development for the treatment of tumors that… 
2014
2014
Food effect substudy of a phase 3 randomized double-blind trial of maintenance with niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor versus placebo in patients with platinum…
e16531 Background: Niraparib is an oral, potent PARP1/2 inhibitor that induces synthetic lethality in BRCA1/2 deficient and… 
2014
2014
A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer ( ENGOT-OV 16 / NOVA trial )
In high grade OC, most deaths occur in the first 36-50 months after diagnosis. Beyond the median survival time, mortality… 
2009
2009
2-pharmaceutically acceptable salts of {4 - - [(3s) piperidin-3-yl] phenyl}-2h-indazole-7-carboxamide